Comparative Immunogenicity Evaluation of Characterized Chitosan-Based and Other Adjuvants for Inactivated Influenza Vaccines
https://doi.org/10.31631/2073-3046-2016-15-1-86-92
Abstract
About the Authors
L. M. KhantimirovaRussian Federation
O. S. Kashirina
Russian Federation
M. I. Chernikova
Russian Federation
Y. M. Vasiliev
Russian Federation
References
1. WHO. Vaccines against influenza WHO position paper. November 2012. WER. 2012; 47: 461 – 476.
2. WHO. Antigenic and genetic characteristics of zoonotic influenza viruses and development of candidate vaccine viruses for pandemic preparedness. WER. 2015; 42: 561 – 571.
3. Vasiliev Y.M. Directions of enhancement for influenza vaccines. Physician. 2014; 8: 12 – 14 (in Russian).
4. Vasiliev Y.M. Neuraminidase inhibitors for specific prophylaxis and therapy of influenza. Physician. 2014; 2: 17 – 19 (in Russian).
5. Kashirina O.S., Vasiliev Y.M. Live attenuated and inactivated influenza vaccines: data from direct comparative studies. Journal of Microbiology. Moscow; 2014; 1: 103 – 119 (in Russian).
6. Chernikova M.I., Vasiliev Y.M. Adjuvanted influenza vaccines: data from direct comparative studies. Journal of Microbiology. Moscow; 2015; 5: 88 – 102 (in Russian).
7. Vasiliev Y. Chitosan-based vaccine adjuvants: incomplete characterization complicates preclinical and clinical evaluation. Expert Review of Vaccines. 2015; 1: 37 – 53.
8. WHO. Manual for the laboratory diagnosis and virological surveillance of influenza. 2011.
9. Khasanova L.M., Il’ina A.V., Varlamov V.P., Sinitsyna O.A., Sinitsyn A.P. Depolymerization of chitosan using an enzyme complex produced by Myceliophthora sp. Applied biochemistry and microbiology. 2014; 4: 422 – 428 (in Russian).
10. Wang W., Bo S., Li S., Qin W. Determination of the Mark-Houwink equation for chitosans with different degrees of deacetylation. International Journal of Biological Macromolecules. 1991; 5: 281 – 285.
11. Hirai A., Odani H., Nakajima A. Determination of degree of deacetylation of chitosan by 1H NMR spectroscopy. Polymer Bulletin. 1991; 1: 87 – 94.
12. Scherlieβß R., Buske S., Young K., Weber B., Rades T., Hook S. In vivo evaluation of chitosan as an adjuvant in subcutaneous vaccine formulations. Vaccine. 2013; 42: 4812 – 4819.
13. Chang H., Li X., Teng Y., Liang Y., Peng B., Fang F. et al. Comparison of adjuvant efficacy of chitosan and aluminum hydroxide for intraperitoneally administered inactivated influenza H5N1 vaccine. DNA and Cell Biology. 2010; 9: 563 – 568.
Review
For citations:
Khantimirova L.M., Kashirina O.S., Chernikova M.I., Vasiliev Y.M. Comparative Immunogenicity Evaluation of Characterized Chitosan-Based and Other Adjuvants for Inactivated Influenza Vaccines. Epidemiology and Vaccinal Prevention. 2016;15(1):86-92. (In Russ.) https://doi.org/10.31631/2073-3046-2016-15-1-86-92